COL18A1 and non-small cell lung carcinoma: In many clinical studies, ICIs combined with antiangiogenic therapy showed good antitumor ability and manageable safety in patients with advanced NSCLC.[17,18] In this study, PD-1 inhibitors combined with recombinant human endostatin and chemotherapy IMRT treatment of advanced NSCLC significantly improved the PFS and ORR of patients.